Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2016, Article ID 5194239, 13 pages
Research Article

Superoxide Dismutase 1 Nanozyme for Treatment of Eye Inflammation

1Chemistry Faculty, M.V. Lomonosov Moscow State University, Moscow 119991, Russia
2Helmholtz Institute for Eye Disease, Moscow 105062, Russia
3UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7362, USA
4Macquarie University, Sydney, NSW 2109, Australia
5Research Institute for Molecular Medicine, I.M. Sechenov First Moscow State Medical University, Moscow 119992, Russia
6Pirogov Russian National Research Medical University, Moscow 117997, Russia

Received 9 April 2015; Revised 6 August 2015; Accepted 12 August 2015

Academic Editor: Felipe Simon

Copyright © 2016 Olga A. Kost et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Use of antioxidants to mitigate oxidative stress during ocular inflammatory diseases has shown therapeutic potential. This work examines a nanoscale therapeutic modality for the eye on the base of antioxidant enzyme, superoxide dismutase 1 (SOD1), termed “nanozyme.” The nanozyme is produced by electrostatic coupling of the SOD1 with a cationic block copolymer, poly(L-lysine)-poly(ethyleneglycol), followed by covalent cross-linking of the complexes with 3,3′-dithiobis(sulfosuccinimidylpropionate) sodium salt. The ability of SOD1 nanozyme as well as the native SOD1 to reduce inflammatory processes in the eye was examined in vivo in rabbits with immunogenic uveitis. Results suggested that topical instillations of both enzyme forms demonstrated anti-inflammatory activity; however, the nanozyme was much more effective compared to the free enzyme in decreasing uveitis manifestations. In particular, we noted statistically significant differences in such inflammatory signs in the eye as the intensities of corneal and iris edema, hyperemia of conjunctiva, lens opacity, fibrin clots, and the protein content in aqueous humor. Clinical findings were confirmed by histological data. Thus, SOD1-containing nanozyme is potentially useful therapeutic agent for the treatment of ocular inflammatory disorders.